Screening for prostate cancer: Defining critical issues

Acta Oncologica

Volumn 50, Issue SUPPL. 1, 2011, Pages 2-3

  Holmberg, Lars ^a,b   Akre, Olof ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

CANCER SCREENING; EDITORIAL; GENETIC MARKER; HUMAN; INFORMED CONSENT; MASS SCREENING; PRIORITY JOURNAL; PROBLEM SOLVING; PROSTATE CANCER; PUBLIC HEALTH SERVICE; TEAMWORK;

EARLY DETECTION OF CANCER; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 79957527701     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.529459     Document Type: Editorial

References (6)

1. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100:1144-54.
2. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/ SFUO-3): An open randomised phase III trial. Lancet 2009; 373(9660):301-8.
3. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360: 1310-9.
4. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320-8.
5. Heinsdijk EAM, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning DJ. Overdetection, overtreatment and costs in prostate-specifi c antigen screening for prostate cancer. Br J Cancer 2009;101:1833-8.
6. Stark JR, Mucci L, Rothman KJ, Adami HO. Screening for prostate cancer remains controversial. BMJ 2009;339: b3601.